About Pulmonx Corporation Common Stock
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Market Cap
$0.27B
Employees
291
Listed Since
October 1, 2020
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Website
www.pulmonx.comPhone
650-364-0400
Headquarters
700 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
CIK
0001127537